

m15H3 vH
h15H3 HA
h15H3 HB
h15H3 HL
h15H3 HN
h15H3 HT
h15H3 HU
m15H3 vL
h15H3 LA
h15H3 LC
h15H3 LF
h15H3 LG

Figure 1





h15H3 HB
% Maximum Binding
100
50
0
0.01
0.1
1
10
100
Competitor (nM)
HBLA
HBLB
HBLC
HBLD
HBLE
HBLF
M15H3

Figure 2

A



B



C

Test Sample	Kd (nM)
m15H3	0.2
h15H3(HBLC)	0.6
h15H3(HTLC)	0.3

Figures 3A-3C



Competition binding of h15H3 to hu B6
m15H3
HL-LC
HL-LG
HN-LC
HN-LG
HB-LC
% Maximum Binding
100
50
0
0.01
0.1
1
10
100
Competitor (nM)

Figure 4



Competition binding of h15H3 to hu B6
% Maximum Binding
100
50
0
0.01
0.1
1
10
100
Competitor (nM)
m15H3
HQ-LC
HQ-LG
HR-LC
HR-LG
HB-LC

Figure 5



Competition binding on hu B6 (293F17) cells
(m15H3-AF488 = 1nM) 12/09/10 LT
m15H3
h15H3 HMLC
h15H3 HMLG
% Maximum Binding
100
50
0
0.01
0.1
1
10
100
1000
Competitor (nM)

Figure 6



Competition Binding on huB6 293F cells
(AF488 = 1nM)
m15H3
h15H3 HBLC
h15H3 HLLC
h15H3 HSLC
h15H3 HTLC
h15H3 HULC
% Maximum Binding
100
50
0
0.01
0.1
1
10
100
1000
Competitor (nM)

Figure 7



Human Multitumor: Bladder (USBiomax: MC5002)
13/20 (65%) = avB6+ (ITGb6-RD)
% area positive
100
75
50
25
-25
5
1
2
1
1
1
1
1
0.7
0
-1
1
2
3
4
5
Staining Intensity

Figure 8




Figure 9A




Figure 9B

Figures 9A-9B




Figure 9C




Figure 9D

Figures 9C-9D




Figure 9E




Figure 9F

Figures 9E-9F



Activity of h15H3-vcMMAE(4) on Detroit 562 Head and Neck Carcinoma
Detroit562-F
MEAN TUMOR VOLUME (mm3)
DAYS POST TUMOR IMPLANT
Untreated
h00-vcMMAE(4) 1 mg/kg
h15H3-vcMMAE(4) 1 mg/kg
h00-vcMMAE 3 mg/kg
h15H3-vcMMAE 3 mg/kg
Schedule q 4 d x 4 IP n=10
0
100
200
300
400
500
600
700
800
900
1000
0
5
10
15
20
25
30
35
40
45
50
55
60
65

Figure 10



Activity of anti αVβ6 ADCs on HPAFII Pancreatic Carcinoma Xenografts in Nude Female Mice
HPAFII-B
MEAN TUMOR VOLUME (mm3)
DAYS POST TUMOR IMPLANT
Untreated
h15H3-1-vcMMAE(4) 3 mg/kg
h00-vcMMAE(4) 3 mg/kg
h15H3-2-vcMMAE(4) 3 mg/kg
dose day
Schedule q 4 d x 4 IP n=7
0
100
200
300
400
500
600
700
800
900
1000
0
5
10
15
20
25
30
35
40
45
50
55
60
65

Figure 11



BxPC3 Pancreatic Xenograft Model
MEAN TUMOR VOLUME (mm³)
1000
800
600
400
200
0
0
10
20
30
40
50
60
70
80
90
100
DAYS POST TUMOR IMPLANT
Untreated
h00-vcMMAE 1 mg/kg
h15H3-vcMMAE 1 mg/kg
h00-vcMMAE 3 mg/kg
h15H3-vcMMAE 3 mg/kg

Figure 12